Virtual transitional pain service delivered via telehealth is effective in preventing new and persistent opioid use amongst post-surgical spine patients

Authors:

Maryam Hussain, PhD (corresponding) Lucid Lane, Inc Affiliation: Lucid Lane, Inc Email: <u>Maryam.hussain1985@gmail.com</u>

Beau Norgeot, PhD Lucid Lane, Inc

Ahmed Zaafran, MD Lucid Lane, Inc

Jessica Stark, MD University of Texas Health Sciences Center McGovern Medical School

John Caridi, MD University of Texas Health Sciences Center McGovern Medical School

Albert Fenoy, MD Northwell Health Feinstein Institutes for Medical Research Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Evan Pivalizza, MBChB University of Texas Health Sciences Center McGovern Medical School

Abstract

Opioid dependence is a national crisis, with 30 million patients annually at risk of becoming persistent opioid users after receiving opioids for post-surgical pain management. Translational Pain Services (TPS) demonstrate effectiveness for behavioral health improvements but its effectiveness in preventing persistent opioid use is less established, especially amongst opioid exposed patients. Prohibitive costs and accessibility challenges have hindered TPS program adoption. To address these limitations, we designed and implemented a remote telehealth TPS protocol focusing on preventing continued opioid use while improving behavioral health. Licensed therapists trained in the opioid-tapering CBT protocol delivered sessions reimbursed through standard payer reimbursement. Our prospective study evaluated the protocol's effectiveness on preventing persistent opioid use and behavioral health outcomes amongst both opioid naïve and exposed patients. In an opioid-naive patient cohort (n=67), 100% completely tapered off opioids, while in an opioid-exposed cohort (n = 19) 52% completely tapered off opioids, demonstrating promising results. In both cohorts, we observed significant improvements in behavioral health scores, including pain. This opioid-tapering digital TPS is effective, adoptable, and incurs no out-of-pocket cost for healthcare systems. We provide the opioid-tapering CBT protocol in the supplement to facilitate adoption. Trial Registration Impact of Daily, Digital and Behavioral Tele-health Tapering Program for Perioperative Surgical Patients Exposed to Opioids and Benzodiazepines registered at clinicaltrials.gov, NCT04787692. https://clinicaltrials.gov/ct2/show/NCT04787692?term=NCT04787692&draw=2&rank=1

Keywords: digital health; opioids; spine surgery; tapering; behavioral health; transitional pain services

1 Introduction

2 3

The opioid epidemic has claimed the lives of over 500,000 people in America.¹ Far from affecting only a

4 marginalized community, many patients are initially exposed to opioids after a surgical or traumatic event. This

5 epidemic has been further accelerated by the COVID pandemic, with a 46% increase in opioid-related overdoses and

6 13% increase in overdose-related deaths from 2019 to 2020.² There are 80 million major surgeries per year in the

7 United States and between 49-95% of those post-surgical patients are discharged with an opioid prescription.^{3–6} This

8 puts approximately 30 million new Americans at an increased risk of persistent opioid use and the severe adverse

9 events associated with it every year.⁷ However, while there are no direct estimates to indicate how many patients

10 receive an opioid tapering care plan, extant literature suggests that most patients are discharged with the expectation

- 11 they will taper on their own.8,9
- 12

13 Post-surgical pain is a major contributor to continued opioid use.¹⁰ Spine surgery is associated with new and

- 14 persistent opioid use, with 13% of opioid naive patients continuing to use opioids for more than 90-days after
- 15 surgery.^{11,12} Risk of continued opioid use varies based on opioid exposure prior to surgery. As such, opioid exposed
- 16 patients, or those who have been using opioids to manage pain prior to surgery, may have different postoperative
- 17 pain expectations and management challenges compared to opioid naive patients, or those who have not been using

18 opioids for pain management prior to surgery.¹³ Furthermore, opioid use is associated with poorer behavioral health

19 outcomes (e.g., depression, anxiety, and quality of life) and increased healthcare costs.¹⁴

20

21 In particular, opioid prescription use, misuse and side effects comprise a significant portion of postoperative health 22 care costs, with some estimates showing that a person with continued opioid use has annual healthcare costs 23 \$14,054-\$20,546 greater than a person who does not use opioids.¹⁵ Findings from an IBM^R Marketscan^R insurance 24 claims database indicate that amongst orthopedic and spine surgery patients, almost 10% have an opioid-related

25 hospitalization and 18% have an emergency room (ER) visit within 90 days after surgery, which can account for

26 around \$32,000 per event in healthcare costs.¹⁶ Similar findings from a separate study using IBM^R MarketScan^R

27 research databases support these findings.¹⁷

28 29 Most surgical patients do not wish to be on opioid therapy,¹⁸ are fearful of dependency, and want to be involved in 30 their tapering process.¹⁹ Transitional pain services (TPS) have demonstrated success in helping patients manage pain 31 after surgery, as well as improve behavioral health outcomes.^{20,21} However, TPS's efficacy in preventing persistent

32 opioid use seems less established. In one study, 27% (n =19) of the patients were still using opioids three months

33 postoperatively, with over half of this cohort (ten of the 19 patients) being opioid naïve preoperatively.²⁰ In another

34 study, opioid tapering results were even more varied: 46% (n = 51) of opioid naïve patients had completely tapered,

35 45% (n = 5 0) had reduced opioid usage, and 8% (n = 9) actually had increased their dosage within the six months

36 after surgery. Tapering results at the six-month postoperative mark were less successful amongst opioid exposed

37 patients: 25% (n = 35) tapered completely, 56% (n = 77) had reduced opioid usage, and 19% (n = 27) had increased

38 their dosage.²¹ Beyond the limitations in completely tapering patients off opioids, brick-and-mortar TPS has not

- 39 been widely adopted,²¹ potentially due to cost and accessibility challenges.^{22,23}
- 40

41 Thus, to address these limitations of brick-and-mortar TPS, we designed a remote telehealth TPS protocol focusing

42 on preventing continued opioid use while improving behavioral health. We incorporated an opioid-tapering CBT

43 protocol as CBT has also been demonstrated to improve post-surgical pain management, behavioral health, and

44 emotional wellbeing.²⁵ Licensed therapists trained in this new protocol digitally delivered sessions to patients, which 45

- were paid through standard payer reimbursements, effectively removing cost and accessibility hurdles. We then 46
- assessed the feasibility and effectiveness of this new TPS protocol through a dual-arm prospective study of opioid 47 naïve and exposed patients undergoing elective spinal surgery at an academic tertiary care hospital. The primary
- 48 outcomes assessed were participant engagement, opioid tapering, and self-reported pain, quality of life, anxiety, and

depression. We did not directly assess cost-savings, but we did track postoperative emergency room visits and
 hospitalizations, which are the major drivers of healthcare cost associated with the opioid epidemic.¹⁷

51

52

53 Results

54 After screening 298, 150 participants were enrolled. Baseline information on participants is presented in Table 1. 55 The majority identified as female ($n = 89, 59 \cdot 3\%$). Race distribution was diverse with 59 $\cdot 2\%$ identifying as White (n = 89), 20 $\cdot 0\%$ African American/Black (n = 30), 19 $\cdot 3\%$ as Hispanic/Latino (n = 29), and 1 $\cdot 3\%$ as Other (n = 2). One 57 hundred and one of participants were opioid naive, and 49 were opioid exposed. Opioid exposed participants had

58 worse baseline behavioral health scores than the opioid naive group on all baseline behavioral health scores (all p <

- 59 0.001) (Table 1 and Supplementary Table 1).
- 60

61 Of the 150 consented cohort, 66.0% of the naive and 55.0% of the exposed participants engaged with aggregate 62 engagement of 63.0% (Figure 1). Engagement was not statistically associated with age, sex, ethnicity, or

63 preoperative behavioral health scores (Supplementary Table 2).

64

There were significant differences in postoperative opioid dosages at the initial therapy session between the opioid

66 naive versus exposed groups (26 MME vs 42 MME), F(1, 85) = 4.7, p = .03, Cohen's f = .21. Both groups saw

67 clinically and statistically significant reductions in dosage at their final postoperative appointment compared to

68 postoperative baseline. The exposed group reduced MME consumption by 65.0% (avg 14 MME), with 53.0% of

69 participants tapering completely off their postoperative opioids (0 MME). Finally, 100% of the opioid naive arm

- patients tapered completely off their postoperative opioids (0 MME). Opioid naïve patients statistically significantly tapered 100% of postoperative opioids compared to opioid exposed patients, $F(1, 85) = 35 \cdot 0$, p < $\cdot 001$, Cohen's f =
- 72

·63.

73

74 By the final postoperative appointment, both groups had statistically and clinically significant improvements in all

behavioral health metrics from initial postoperative scores, which are presented as median with interquartile range

76 (IQR). The opioid naive arm (Figure 2) had 43.7% improvement in pain (baseline VAS = 5.5, IQR = 4.3; final

77 VAS = 3.0, IQR = 2.0), 17.5% improvement in QoL (baseline EQ5D5L= 67.8, IQR = 27.5; final EQ5D5L= 77.5,

78 IQR = 13.6), 6.3% improvement in functioning (baseline GAF = 75.0, IQR = 15.0; final GAF = 85.0, IQR = 9.0),

79 27.0% improvement in common symptoms (baseline ESAS = 26.0, IQR = 16.0; final ESAS = 20.0, IQR = 23.0),

80 66.7% improvement in anxiety (baseline GAD7 = 3.0, IQR = 6.0; final GAD7 = 0.0, IQR = 3.0), and 72.7%

81 improvement in depression (baseline PHQ9 = 4.0, IQR = 8.0; final PHQ9 = 0.0, IQR = 4.0). See Supplementary 82 Table 3 for Wilcoxon signed rank test statistics.

83

84 The opioid exposed arm (Figure 3) had 33.3% improvement in pain (baseline VAS = 6.0, IQR = 5.0; final VAS =

4.0, IQR = 2.0), 100.0% improvement in QoL (baseline EQ5D5L= 44.0, IQR = 58.3; final EQ5D5L= 79.6, IQR = 2.0), 100.0% improvement in QoL (baseline EQ5D5L= 44.0, IQR = 58.3; final EQ5D5L= 79.6, IQR = 2.0), 100.0% improvement in QoL (baseline EQ5D5L= 44.0, IQR = 58.3; final EQ5D5L= 79.6, IQR = 2.0), 100.0% improvement in QoL (baseline EQ5D5L= 44.0, IQR = 58.3; final EQ5D5L= 79.6, IQR = 2.0), 100.0% improvement in QoL (baseline EQ5D5L= 44.0, IQR = 58.3; final EQ5D5L= 79.6, IQR = 2.0), 100.0% improvement in QoL (baseline EQ5D5L= 44.0, IQR = 58.3; final EQ5D5L= 79.6, IQR = 2.0, 100.0 (baseline EQ5D5L= 100.0), 100.0 (ba

86 19.4), 9.4% improvement in functioning (baseline GAF = 72.0, IQR = 12.0; final GAF = 80.0, IQR = 15.0), 34.6%

87 improvement in common symptoms (baseline ESAS = 33.0, IQR = 5.0; final ESAS = 21.0, IQR = 25.5), 82.1%

improvement in anxiety (baseline GAD7 = 9.5, IQR = 12.0; final GAD7 = 2.0, IQR = 4.0), and 57.3%

improvement in depression (baseline PHQ9 = 11.5, IQR = 11.5; final PHQ9 = 3.0, IQR = 5.5). See Supplementary

- 90 Table 4 for Wilcoxon signed rank test statistics.
- 91

There were no high-cost healthcare utilization events, particularly postoperative ER visits and/or re-hospitalizations,
 observed for any patient in either opioid naive or exposed groups (Table 2).

- 95 Discussion
- 96

97 In this feasibility trial of 150 participants undergoing elective spine surgery who were enrolled into a virtual TPS

- 98 with goals of opioid tapering and postoperative pain management facilitated through CBT delivered through a
- telehealth platform, we found that: i) engagement was high, ii) tapering to zero MMEs was achievable by all naive
- patients and most opioid exposed participants, iii) pain and other behavioral health scores improved significantly, and iv) no high-cost healthcare utilizations occurred, such as ER visits or rehospitalizations. Baseline socio-
- 101 and iv) no high-cost healthcare utilizations occurred, such as ER visits or rehospitalizations. Baseline socio-102 demographic, economic or clinical variables were not associated with any of the primary study outcomes. These
- 102 demographic, economic or clinical variables were not associated with any of the primary study outcomes. These 103 results indicate that TPS facilitated by CBT-focused opioid tapering can be implemented virtually through telehealth
- 104 with measurable benefits to postoperative patients.
- 105

106 Study engagement, defined as attendance in one or more post-surgical CBT-TPS sessions, was over 60% which is

107 considerably higher than 20-40% reported engagement for telehealth studies among spine surgery patients.^{33,34} Of 108 patients within the TPS at Toronto General Hospital, 41.3% engaged with the Manage My Pain mobile health

109 platform.³⁵ The higher levels of engagement seen in our study may be due to the structured nature of the program,

- 110 which included clear preoperative expectation about the patient journey and explicit communication of opioid
 - 111 tapering as the goal defined by the CBT-focused protocol.
 - 112

113 Approximately 13% of orthopedic spine surgery patients develop new persistent opioid use,¹² making it a common

114 post-surgical complication. Existing studies indicate that compared to preoperative use, 33% of opioid exposed

patients increase, 33% decrease and 33% remain at the same MME postoperatively over a 12-month period.³⁶ In our

116 study, no participant increased their postoperative MME dosage. All engaged opioid naive participants (n = 67) 117 tapered 100% off their postoperative opioids within 90 days (0 MME). These results compare favorably to an in-

person TPS study in which, six months after surgery, only 46% (n = 51) of the opioid naive cohort tapered

119 completely, and 8% (n = 9) actually increased their opioid usage.²¹ Seventy-four percent of opioid exposed

120 participants reduced postoperative opioid MME by at least 50%. Interestingly, over half (53%) of exposed

participants reduced postoperative opioid while by at least 50%. Interestingly, over nan (55%) of exposed participants reduced their postoperative MME by 100%, thereby completely tapering off the opioid. These results

also standout in comparison to an in-person TPS study in which, six months after surgery, 25% (n = 35) of opioid

123 exposed patients had completely tapered off their postoperative opioids, and 19% (n = 27) increased their opioid

124 usage.²¹

125

126 Opioids are often prescribed for postoperative analgesia. While the tapering results presented here are notable, it is

127 unclear how they alone impact patients' quality of life. We observed clinically and statistically significant

improvements across all behavioral health symptoms, including depression, anxiety, QoL, and pain amongst both naive and exposed arms. These results are particularly important when viewed within the context of in-person TPS

130 that did not utilize a CBT-focused protocol. While our study does not have matching inclusion criteria to the in-

131 person TPS study at Toronto General Hospital, some comparison is warranted. Participants in our CBT-guided vTPS

study experienced twice the improvement in pain symptoms, 5 times the reduction in depression, and 10 times the

reduction in anxiety as was reported for patients in the landmark TPS study.³⁷

134

135 The estimated economic costs of the US opioid epidemic topped \$1 trillion in 2017.³⁸ The largest drivers of direct

136 healthcare costs associated with post-surgical opioid use are ER visits and re-hospitalizations, with these events

137 occurring at a rate of over 400 per thousand patients (see Table 3).¹⁷ The fact that zero events occurred for any of the

138 96 patients completed this study is a promising indication that successful tapering while improving behavioral health

- 139 could also potentially result in lower healthcare cost and utilization.³⁶
- 140

141 While the results presented here are encouraging, the study has several limitations. The percentage of opioid

142 exposed participants that completed the study was low. Patients with a history of opioid use for chronic pain are at

risk of other surgical complications,³⁹ and we saw several of these participants needing to leave the study because

144 they required additional spine surgeries. While the outcomes observed here for exposed participants were

145 statistically significant, a larger opioid exposed study size is needed in the future, including direct measures of the

146 cost of implementing a program and subsequent economic benefit. The study was designed to test the feasibility of

vTPS with greater incorporation of CBT-focused opioid tapering, so randomization was not used. Thus, we were

148 unable to isolate the effect of improved pain and behavioral health over time in a non-therapy group. Further

149 randomized studies are needed to evaluate vTPS over existing standards of care, although these promising findings

150 may lead to ethical considerations if participants are required to be randomized to no therapy.

151

152 In summary, this study explored the feasibility of implementing a virtual TPS in a dual arm prospective trial of 150

153 opioid naive and opioid exposed participants from diverse backgrounds undergoing spinal surgery. Engagement was

high, most participants tapered completely off opioids within 3 months regardless of study arm. Pain and behavioral health scores improved clinically, as well as statistically, and no high-cost opioid-related healthcare utilization

events occurred. While traditional TPS programs are known to be effective for behavioral health, they may have

157 limitations to greatly reduce postoperative opioid use and may be costly to implement. The evidence from this study

158 indicates that a virtual TPS can offer significant health benefits while preventing new and persistent opioid use, and

159 would likely be feasible for most hospitals to adopt.

160161 Methods

162

163 The Committee for the Protection of Human Subjects at the University of Texas Health Science Center Houston 164 (IRB NUMBER: HSC-MS-20-0549) approved the study. All participants gave verbal and written consent to 165 participate. The study was registered at clinicaltrials.gov, identifier NCT04787692. De-identified data will be 166 provided upon request.

167

168 *Outcome measures* The primary outcomes were engagement with the CBT program after surgery, opioid tapering
 169 and improvements in behavioral health. We defined engagement as the participants attending at least one session
 170 with their assigned therapist after surgery.

171

We assessed opioid tapering by percent reduction from postoperatively prescribed opioids, which were standardized
to morphine milligram equivalents (MME). For opioid naive participants, opioid tapering was assessed within 90
days after surgery and for opioid exposed participants, opioid taper was assessed within 180 days after surgery.

175

Participants reported pain, quality of life, functioning, general health symptoms, and anxiety and depression
symptoms. We utilized validated, reliable survey instruments to assess these measures of behavioral health (See
Supplementary Figure 1).

179

180

181 Study Procedures

182

183 We recruited adult patients (aged 18 years or older) scheduled for elective orthopedic or neurosurgical spine surgery 184 from the Anesthesia Preoperative Clinic at Memorial Hermann Hospital in the Texas Medical Center, the teaching 185 facility associated with McGovern Medical School at UTHealth-Houston. Eligibility inclusion and exclusion criteria 186 are shown in Supplementary Figure 2. After consent, the pre-surgery session was performed with collection of 187 participants self-reported sociodemographic information and behavioral health surveys. Information regarding 188 opioid exposure was cross referenced from the medical record.

189

190 At the time of study initiation, state mandated, COVID-19 hospital restrictions were implemented which led to

191 interruption of scheduled elective surgery. In addition, for several periods, the pre-operative clinic functioned

192 virtually with no in-patient visits. During these times, surgical co-investigators mentioned the study to subjects in

193 preoperative visits and presented study details to subjects after arrival for their scheduled procedure by members of

194 the research team. If the patient consented, enrollment and study procedures took place in a private room in the day

surgery unit. Despite these unforeseen restrictions, study procedures continued as elective surgery was scheduled, and screening and enrollment resumed in-person once the pre-operative assessment clinic was opened.

197

198 Participants were scheduled for their initial therapy session, which was within seven days of discharge from the 199 hospital, at the pre-operative screening. Therapy sessions occurred via HIPAA-compliant audio/video-calling 200 platform, through a single-use link. Licensed therapists at Lucid Lane provided therapy services. Lucid Lane (Palo 201 Alto, CA) is a telehealth company that focuses on administering CBT-facilitated tapering virtually (i.e., through 202 HIPAA-compliant audio/video platforms) to perioperative patients, as well as other pain or general mental health 203 patients. For the study, opioid naive participants received one one-hour session weekly for up to four weeks, to be 204 used consecutively, after which they received a 90-day postoperative follow-up. At the first and last therapy sessions 205 and at the follow-up, therapists asked participants to complete the behavioral health surveys and opioid use details 206 (i.e., dosage and frequency of use). Therapists also tracked self-reported high-cost healthcare utilization events such 207 as ER visits and re-hospitalizations. Opioid exposed participants received one one-hour session weekly for up to 26 208 weeks (180 days), to be used consecutively. If the patient dropped off weekly sessions prior to 26 weeks, the 209 therapist conducted follow-up at 30-, 90- or 180-days post-operatively, depending on when the participants stopped 210 attending therapy sessions. Participants were automatically removed from therapy sessions if they missed or could 211 not be contacted for three consecutive appointments. There was no charge to participants for the therapy services.

212

A series of power analyses to compute achievable power were run using the Monte Carlo procedure in MPlus.^{28,29}

We included variances based on preliminary data from existing Lucid Lane patients (rep corr = 0.3 to 0.5) and a nonsphericity correction $\varepsilon = .5$, such that 1/[repetitions-1], while holding all other parameters constant. Due to high

attrition rates (between 25 and 50%) from psychological interventions targeting treatment of opioid use, ³⁰ we

217 sought to consent n = 150 subjects, with anticipated subject fall-out of the postoperative therapy sessions, to detect

- 218 medium effects (f = 0.25, $\alpha = 0.05$). We conducted post-hoc sensitivity power analyses to identify power and
- 219 detectable effect size based on the attrition samples. Based on a sample size n = 67 (opioid naïve), analyses indicated 220 80% power to detect at least small-to-medium effects (d = $\cdot 30$, $\alpha = 0.05$), and for n = 19 (opioid exposed), 80%
- 221 power to detect at least medium-to-large effects (d = 50, d = 0.05).
- 222

223 Lucid Lane therapists collected therapy data, with surgical and anesthesiology investigators blinded from these 224 findings. We used IBM SPSS v 27 (Armonk, NY) to analyze: i) descriptive statistics, used for participants 225 sociodemographic, pre-surgery and post-surgery behavioral health characteristics, ii) odds-ratio analyses, used to 226 determine probability of engaging based on pre-surgery characteristics, iii) analysis of variance (ANOVA), used to 227 determine differences in preoperative behavioral health scores based on opioid group (naïve vs exposed), iv) odds-228 ratio analyses, used to determine probability of meeting tapering goal based on pre-surgery characteristics and 229 behavioral health, and v) Wilcoxon signed rank tests, used to determine changes in behavioral health from the first 230 session to the final session. We report median values with interquartile ranges, which is best practice for clinical trial 231 data that are skewed and cannot be normalized.^{31,32}

232

We preserved participant confidentiality by storing paper informed consent forms and pre-surgical survey
 instruments in a locked office in the medical school building of the study PI. Furthermore, all electronic data were
 maintained on a HIPAA-compliant BOX folder.

236

237

- Death Rate Maps & Graphs | Drug Overdose | CDC Injury Center. CDC. Published October 7, 2022. Accessed
 December 1, 2022. https://www.cdc.gov/drugoverdose/deaths/index.html
- Manchikanti L, Vanaparthy R, Atluri S, Sachdeva H, Kaye AD, Hirsch JA. COVID-19 and the Opioid
 Epidemic: Two Public Health Emergencies That Intersect With Chronic Pain. *Pain Ther*. 2021;10(1):269-286.
 doi:10.1007/s40122-021-00243-2
- Hall MJ, Schwartzman A, Zhang J, Liu X. Ambulatory Surgery Data From Hospitals and Ambulatory Surgery Centers: United States, 2010. *Natl Health Stat Rep.* 2017;(102):1-15.
- NQF: NQF-Endorsed Measures for Surgical Procedures. Accessed December 1, 2022.
 https://www.qualityforum.org/Publications/2015/02/NQF-Endorsed_Measures_for_Surgical_Procedures.aspx
- 5. Bartels K, Mayes LM, Dingmann C, Bullard KJ, Hopfer CJ, Binswanger IA. Opioid Use and Storage Patterns by Patients after Hospital Discharge following Surgery. *PLOS ONE*. 2016;11(1):e0147972. doi:10.1371/journal.pone.0147972
- Nooromid MJ, Blay E, Holl JL, et al. Discharge prescription patterns of opioid and nonopioid analgesics after common surgical procedures. *Pain Rep.* 2018;3(1):e637. doi:10.1097/PR9.00000000000637
- Jain N, Phillips FM, Weaver T, Khan SN. Preoperative Chronic Opioid Therapy: A Risk Factor for
 Complications, Readmission, Continued Opioid Use and Increased Costs After One- and Two-Level Posterior
 Lumbar Fusion. *Spine*. 2018;43(19):1331-1338. doi:10.1097/BRS.00000000002609
- 257 8. Uhrbrand P, Phillipsen A, Rasmussen MM, Nikolajsen L. Opioid tapering after spine surgery: Protocol for a randomized controlled trial. *Acta Anaesthesiol Scand*. 2020;64(7):1021-1024. doi:10.1111/aas.13576
- Vincent S, Paskey T, Critchlow E, et al. Prospective Randomized Study Examining Preoperative Opioid
 Counseling on Postoperative Opioid Consumption after Upper Extremity Surgery. *HAND*. 2022;17(2):200-205.
 doi:10.1177/1558944720919936
- Dahlhamer J, Lucas J, Zelaya, C, et al. Prevalence of Chronic Pain and High-Impact Chronic Pain Among
 Adults United States, 2016. *Morb Mortal Wkly Rep.* 2018;67(36):1001-1006.
 doi:10.15585/mmwr.mm6736a2
- Brummett CM, Waljee JF, Goesling J, et al. New Persistent Opioid Use After Minor and Major Surgical
 Procedures in US Adults. *JAMA Surg.* 2017;152(6):e170504. doi:10.1001/jamasurg.2017.0504
- 267 12. Deyo RA, Hallvik SE, Hildebran C, et al. Use of Prescription Opioids before and After an Operation for
 268 Chronic Pain (Lumbar Fusion Surgery). *Pain*. 2018;159(6):1147-1154. doi:10.1097/j.pain.00000000001202
- Macintyre PE, Roberts LJ, Huxtable CA. Management of Opioid-Tolerant Patients with Acute Pain:
 Approaching the Challenges. *Drugs*. 2020;80(1):9-21. doi:10.1007/s40265-019-01236-4
- 14. Jacobs CA, Hawk GS, Jochimsen KN, et al. Depression and Anxiety Are Associated With Increased Health Care Costs and Opioid Use for Patients With Femoroacetabular Impingement Undergoing Hip Arthroscopy: Analysis of a Claims Database. *Arthrosc J Arthrosc Relat Surg*. 2020;36(3):745-750.
 274 doi:10.1016/j.arthro.2019.09.048
- 15. Meyer R, Patel AM, Rattana SK, Quock TP, Mody SH. Prescription Opioid Abuse: A Literature Review of the Clinical and Economic Burden in the United States. *Popul Health Manag*. 2014;17(6):372-387. doi:10.1089/pop.2013.0098

- Hussain M, Norgeot B, Zaafran A, Pivalizza E. Using a telehealth tapering platform can save opioid use and opioid-related hospitalization costs after spine surgery. Presented at: American Society of Regional Anesthesia and Pain Medicine; November 17, 2022; Orlando, FL.
- 17. Brummett CM, Evans-Shields J, England C, et al. Increased health care costs associated with new persistent opioid use after major surgery in opioid-naive patients. *J Manag Care Spec Pharm*. 2021;27(6):760-771.
 283 doi:10.18553/jmcp.2021.20507
- 284 18. van Dijk JFM, Kappen TH, Schuurmans MJ, van Wijck AJM. The Relation Between Patients' NRS Pain
 285 Scores and Their Desire for Additional Opioids after Surgery. *Pain Pract*. 2015;15(7):604-609.
 286 doi:10.1111/papr.12217
- 19. Uhrbrand P, Phillipsen A, Dreyer P, Nikolajsen L. Opioid tapering after surgery: a qualitative study of patients' experiences. *Scand J Pain*. 2020;20(3):555-563. doi:10.1515/sjpain-2019-0168
- 289 20. Huang A, Azam A, Segal S, et al. Chronic postsurgical pain and persistent opioid use following surgery: the need for a transitional pain service. *Pain Manag.* 2016;6(5):435-443. doi:10.2217/pmt-2016-0004
- 291 21. Katz J, Weinrib AZ, Clarke H. Chronic postsurgical pain: From risk factor identification to multidisciplinary 292 management at the Toronto General Hospital Transitional Pain Service. *Can J Pain*. 2019;3(2):49-58.
 293 doi:10.1080/24740527.2019.1574537
- 294 22. Rosenquist RW, Mariano ER. The Future of Pain Medicine. ASA Monit. 2021;85(S10):35-37. doi:10.1097/01.ASM.0000795180.24248.c5
- 23. Sun EC, Mariano ER, Narouze S, et al. Making a business plan for starting a transitional pain service within the
 US healthcare system. *Reg Anesth Pain Med*. 2021;46(8):727-731. doi:10.1136/rapm-2021-102669
- 24. Weinrib AZ, Burns LC, Mu A, et al. A case report on the treatment of complex chronic pain and opioid
 dependence by a multidisciplinary transitional pain service using the ACT Matrix and buprenorphine/naloxone.
 J Pain Res. 2017;10:747-755. doi:10.2147/JPR.S124566
- 301 25. McCracken LM, Turk DC. Behavioral and Cognitive–Behavioral Treatment for Chronic Pain: Outcome,
 302 Predictors of Outcome, and Treatment Process. *Spine*. 2002;27(22):2564.
- Murphy R, Calugi S, Cooper Z, Grave RD. Challenges and opportunities for enhanced cognitive behaviour therapy (CBT-E) in light of COVID-19. *Cogn Behav Ther*. 2020;13:e14. doi:10.1017/S1754470X20000161
- 27. Dario AB, Moreti Cabral A, Almeida L, et al. Effectiveness of telehealth-based interventions in the
 management of non-specific low back pain: a systematic review with meta-analysis. *Spine J.* 2017;17(9):1342-1351. doi:10.1016/j.spinee.2017.04.008
- 308
 308 28. Bolger N, Laurenceau JP. Intensive Longitudinal Methods: An Introduction to Diary and Experience Sampling Research. Guilford Press; 2013:xv, 256.
- 310 29. Muthen LK, Muthen BO. Mplus user guide Ver_7_r6_web.pdf. Mplus: Statistical Analysis with Latent
 311 Variables. Published 2017. Accessed January 4, 2023.
 312 https://www.statmodel.com/download/usersguide/Mplus%20user%20guide%20Ver 7 r6 web.pdf
- 30. Brown AR. A Systematic Review of Psychosocial Interventions in Treatment of Opioid Addiction. J Soc Work Pract Addict. 2018;18(3):249-269. doi:10.1080/1533256X.2018.1485574
- 31. Ou FS, Le-Rademacher JG, Ballman KV, Adjei AA, Mandrekar SJ. Guidelines for Statistical Reporting in
 Medical Journals. *J Thorac Oncol.* 2020;15(11):1722-1726. doi:10.1016/j.jtho.2020.08.019

- 317 32. Charan J, Saxena D. Suggested statistical reporting guidelines for clinical trials data. *Indian J Psychol Med.* 2012;34(1):25-29.
- 319 33. Gannon J, Atkinson JH, Chircop-Rollick T, et al. Telehealth Therapy Effects of Nurses and Mental Health
 Professionals From 2 Randomized Controlled Trials for Chronic Back Pain. *Clin J Pain*. 2019;35(4):295-303.
 doi:10.1097/AJP.0000000000678
- 322 34. Fernandes LG, Devan H, Kamper SJ, Williams CM, Saragiotto BT. Enablers and barriers of people with
 chronic musculoskeletal pain for engaging in telehealth interventions: protocol for a qualitative systematic
 review and meta-synthesis. *Syst Rev.* 2020;9(1):122. doi:10.1186/s13643-020-01390-x
- 325 35. Slepian PM, Peng M, Janmohamed T, et al. Engagement with Manage My Pain mobile health application among patients at the Transitional Pain Service. *Digit Health*. 2020;6:2055207620962297. doi:10.1177/2055207620962297
- 328 36. Rishel CA, Angst MS, Sun EC. Preoperative Opioid Utilization Patterns and Postoperative Opioid Utilization:
 329 A Retrospective Cohort Study. *Anesthesiology*. 2021;135(6):1015-1026. doi:10.1097/ALN.000000000004026
- 330 37. Abid Azam M, Weinrib AZ, Montbriand J, et al. Acceptance and Commitment Therapy to manage pain and
 331 opioid use after major surgery: Preliminary outcomes from the Toronto General Hospital Transitional Pain
 332 Service. *Can J Pain*. 2017;1(1):37-49. doi:10.1080/24740527.2017.1325317
- 333
 38. Kuehn BM. Massive Costs of the US Opioid Epidemic in Lives and Dollars. *JAMA*. 2021;325(20):2040.
 doi:10.1001/jama.2021.7464
- 39. Yerneni K, Nichols N, Abecassis ZA, Karras CL, Tan LA. Preoperative Opioid Use and Clinical Outcomes in
 Spine Surgery: A Systematic Review. *Neurosurgery*. 2020;86(6):E490. doi:10.1093/neuros/nyaa050
- 337
- 338

339

340

540

341

342

344 Author Contributions

- 345 MH: Lucid Lane PI, biostatistician, lead author, study design, administration of the study protocol, data maintenance
- 346 and management, data analysis, initial complete manuscript draft, manuscript editing/reviewing.
- 347 BN: co-author, literature review, writing contributions to major sections of manuscript, manuscript feedback,
- 348 editing/reviewing.
- 349 AZ: co-author, study design, manuscript feedback.
- 350 JS: co-author, access to resources/materials, manuscript feedback.
- 351 JC: co-author, access to resources/materials, manuscript feedback.
- 352 AF: co-author, access to resources/materials, manuscript feedback.
- 353 EP: UT Houston PI, study design, administration of the study protocol, access to resources/materials, manuscript
- 354 feedback.
- 355


356 Data Availability Statement

- All data will be made available upon publication. It will be available in deidentified format.
- 358

359 Competing Interests Statement

- 360 MH is a salaried employee of Lucid Lane, Inc., has stock options in Lucid Lane, Inc., and has received conference
- travel support from Lucid Lane, Inc. BN is a salaried employee of Lucid Lane, Inc. and Anthem, Inc., has stock
- 362 options in Lucid Lane, Inc. and Anthem, Inc., and has patents planned from Lucid Lane, Inc. and Anthem, Inc. AZ is
- 363 a salaried employee of Lucid Lane, Inc., and Lucid Lane Providers, P.C., has received travel support from Lucid
- Lane, Inc., is on the leadership board of Lucid Lane and Board of Directors, and is on the Advisory Board of the
- 365 American Festival for Thy Arts. JS has no competing interests. JC has received teaching payment from Stryker
- 366 Spine. AF has grant support from NIH NINDS R01 #NS113893, and participates on the Data Safety Monitoring
- 367 Board/Advisory Board of Medtronic. EP served as President for the Texas Society of Anesthesiologists, and serves
- 368 as a Medical Consultant with future stock options at Lucid Lane, Inc.


370 Figures



373 Figure 1. CONSORT Diagram

* n = 152 consented; however, n = 2 were promptly removed from consent procedures due to cancellation of

- 375 surgical procedure






382 Figure 2. Behavioral health changes within 90-days for the opioid naive arm

383 *Note*. Reduced scores in anxiety, depression, pain, and general symptoms indicate improvement. Increased scores in

384 functioning and quality of life indicate improvement. All behavioral health median changes were statistically

385 significantly different from the first appointment to the final appointment (p < 001).



387

388

389

390 Figure 3. Behavioral health changes with statistical significance for the Opioid Exposed Arm

391 *Note.* Reduced scores in anxiety, depression, pain, and general symptoms indicate improvement. Increased scores in

392 functioning and quality of life indicate improvement. All behavioral health changes were statistically significantly

393 different from the first appointment to the final appointment (p < 05).

395 Tables

396

397 Table 1. Patient Preoperative Characteristics

| Characteristic | n | Mean (SD) or % | |
|--------------------------------|-----|----------------|--|
| Age (years) | | 56.6 (12.8) | |
| Sex | | | |
| Male | 62 | 41.3% | |
| Female | 88 | 58.7% | |
| Other | 0 | 0.0% | |
| Ethnicity | | | |
| Black/African American | 30 | 20.0% | |
| Hispanic/Latino | 29 | 19.3% | |
| White | 89 | 59.3% | |
| Other | 2 | 1.3% | |
| Preoperative opioid use | | | |
| Yes (Opioid Exposed) | 49 | 32.70% | |
| No (Opioid Naive) | 101 | 67.30% | |
| Preoperative Behavioral Health | | | |
| Pain ^a | | 6.6 (2.5)* | |
| QoL ^b | | 57.5 (27.7)* | |
| Functioning | | 73.8 (11.6)* | |
| Depression ^d | | 7.7 (6.4)* | |
| Anxiety ^e | | 7.3 (5.9)* | |
| Symptoms ^r | | 29.5 (19.8)* | |

^aVisual Analog Scale (numerical rating 0-10)

^bEuropean Quality of Life EQ5D5L composite score (0-100)

^cGlobal Assessment of Functioning (numerical rating 0-100)

^dPatient Health Questionnaire-9 total score

eGeneralized Anxiety Disorder-7 total score

^fEdmonton Symptoms Assessment Survey total score

*a statistically significantly higher pain symptoms for opioid exposed, F(1,149) = 19.9, p < .001, Cohen's f = .35

*b statistically significantly lower QoL for opioid exposed, $F(1,149) = 22 \cdot 4$, p < $\cdot 001$, Cohen's $f = \cdot 38$

*c statistically significantly lower functioning for opioid exposed, $F(1,149) = 25 \cdot 5$, $p < \cdot 001$, Cohen's $f = \cdot 40$

*^d statistically significantly higher depression symptoms for opioid exposed, F(1,149) = 20.9, p < $\cdot 001$, Cohen's $f = \cdot 36$

*e statistically significantly higher anxiety symptoms for opioid exposed, $F(1,149) = 11 \cdot 1$, $p = \cdot 001$, Cohen's $f = \cdot 26$

*f statistically significantly higher overall symptoms for opioid exposed, F(1,149) = 20.9, p < .001, Cohen's f = .36

398

399

400

402 Table 2. Comparison of healthcare utilization within 90-days postoperative period, IBM^R Marketscan^R Data

403 and Lucid Lane Data

| Major Incidence | - Claim Type | IBM MarketScan MSK Surgery with Opioid Prescription within 14 Days of Surgery (2018) | | Lucid Lane Spine Surgery with Opioid Prescription after Surgery (2020-2021) | |
|------------------------|--------------------------------------|--|--------------------|---|--------------------|
| | | Utilization per 1000 | Cost per Unit (\$) | Utilization per 1000 | Cost per Unit (\$) |
| Inpatient Admission | Hospital Admission within 90 Days | 194.5 | 37,750.53 | 0 | C |
| Facility Outpatient | Emergency Room within 90 Days | 425 | 2,354.08 | 0 | (|